Blood stem cell transplants have been central players in treating blood cancers for decades. These procedures can improve patients’ chances of survival and can even offer the opportunity for a cure in some cases. But over the last decade, physicians say they’ve started doing transplants for fewer cancer types, particularly lymphomas, and are instead reaching first for newer immune or targeted therapies that are safer and often more effective.
A complete organized library of all my videos, digital slides, pics, & sample pathology reports is available here: https://kikoxp.com/posts/5084 (dermpath) &…
Fauxcoll gradient, Blood, Volume 115, Issue 13, 1 April 2010, Pages 2567, https://doi.org/10.1182/blood-2010-03-272575
Pediatric solid tumors are a leading cause of childhood disease mortality. In this work, we examined germline structural variants (SVs) as risk factors for pediatric…
He’ll be chief of radiation oncology.
Of course, they made a few predictions, too.
Physicians at Mass General Brigham, Beth Israel, and Cambridge Health Alliance are driven by a conviction that their employers are putting business considerations over medical…
We’re on a journey to advance and democratize artificial intelligence through open source and open science.
Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of all
Current evaluation of treatment response in solid tumors depends on dynamic changes in tumor diameters as measured by imaging. However, these changes can only be…
Nature Medicine – Results from this single-arm cohort of the BFAST trial showed that the clinical efficacy of entrectinib in patients with ROS1-positive NSCLC, selected…
